ALK and pneumonitis: Furthermore, patients who received chemotherapy prior to treatment with ALK TKIs were more likely to develop all‐grade pneumonitis (7.73%, 95% CI: 4.39%–11.85%) compared with those who received first‐line ALK TKI treatment (2.26%, 95% CI: 1.23%–3.54%) and previously treated group (2.68%, 95% CI: 1.23%–4.55%); however, the difference was not significant (p = 0.21) (Supplementary Table 1).